Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases

Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases

Saved in:

Bibliographic Details
Main Author:	Frontiers Production Office
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	chronic disease inactivated quadrivalent influenza vaccine 23-valent pneumococcal polysaccharide vaccine simultaneous administration immunogenicity safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1682368/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Wanqin Tang, et al.
Published: (2025-08-01)

Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
by: B. Ts. Batozhargalova, et al.
Published: (2024-09-01)

INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: G. M. Tarasova, et al.
Published: (2018-09-01)

Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
by: G. M. Tarasova, et al.
Published: (2021-06-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016-12-01)

EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: M. S. Naumtseva, et al.
Published: (2015-05-01)

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories
by: Feng Wen, et al.
Published: (2025-12-01)

13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case
by: Ekaterina I. Alekseeva, et al.
Published: (2019-09-01)

Results of Clinical Trials of the First Russian 4-valent Flu Vaccine
by: D. A. Lioznov
Published: (2018-09-01)

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up
by: Lili Huang, et al.
Published: (2025-12-01)

A Decade of Experience in the use of 13-Valent Conjugated Polysaccharide Pneumococcal Vaccine in Russian Federation
by: N. I. Briko, et al.
Published: (2023-09-01)

Safety and immunogenicity of inactivated Zika virus vaccine by gamma irradiation
by: Pumin Sintara, et al.
Published: (2025-10-01)

Pneumococcal Vaccine Uptake in Adults Before and After Hospitalization for Pneumococcal Infections in Hong Kong, 2015 to 2024
by: King-Pui Florence Chan, et al.
Published: (2025-05-01)

Factors associated with the intention to vaccinate and price sensitivity to the human papillomavirus (HPV) vaccine among Chinese male medical college students: a cross-sectional survey
by: Yuan Li, et al.
Published: (2025-06-01)

Pneumococcal Vaccine for Infants and Toddlers
by: T. Mitchell
Published: (2006-08-01)

Evaluation of determinants of the serological response to the quadrivalent split‐inactivated influenza vaccine
by: Shaohuan Wu, et al.
Published: (2022-05-01)

Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States
by: Zinan Yi, et al.
Published: (2024-11-01)

Efficacy of usage of pneumococcal 7-valent vaccine in prophylaxis of pneumococcal infection in Novosibirsk children from risk groups
by: O. A. Beletskaya, et al.
Published: (2013-03-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

Clinical and Economic Efficiency of Vaccination in a Pneumococcal 13-Valent Conjugate Vaccine in Patients with Chronic Bronchitis at a Young Age
by: G. L. Ignatova, et al.
Published: (2017-04-01)

A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years
by: Jose Luis Huerta, et al.
Published: (2025-08-01)

Review of global use of licensed vaccines and development of new vaccines for the prevention of pneumococcal infection
by: M. V. Savkina, et al.
Published: (2021-12-01)

Immunogenicity analysis of a composition of inactivated human rotavirus A strains in mice following immunisation
by: M. V. Kovrizhko, et al.
Published: (2024-12-01)

Modern Approaches to Vaccinal Prevention of a Pneumococcal Infection in Adults Patients with Diabetes Mellitus (Literature Review)
by: J. A. Paramonova, et al.
Published: (2018-04-01)

Effect of Vaccination against Pneumococcal Infection and Influenza on the Clinical Course of Bronchial Asthma
by: N. P. Andreeva, et al.
Published: (2019-09-01)

Association Between Introduction of the 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) and Pneumonia Incidence and Mortality Among General Older Population in Japan: A Community-based Study
by: Aya Sugiyama, et al.
Published: (2025-05-01)

Efficacy and Safety of Immunization With Pneumococcal Polysaccharide Vaccine in Children With Juvenile Idiopathic Arthritis: Preliminary Results of a Prospective Open-Label Study
by: Ekaterina I. Alexeeva, et al.
Published: (2017-06-01)

Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01)

ASSESSMENT OF VACCINATION PROGRAM EFFECTIVENESS: BASIC APPROACHES AND ISSUES
by: N. I. Briko, et al.
Published: (2014-07-01)

Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China
by: Ruogu Meng, et al.
Published: (2025-12-01)

Pneumococcal Infection and Vaccination-Related Knowledge, Attitudes and Practices Among Saudi Residents
by: Wed S. Althobaiti, et al.
Published: (2025-07-01)

Risk of developing juvenile idiopathic arthritis after quadrivalent HPV vaccination: a retrospective cohort study using the TriNetX U.S. Network
by: Wen-Yu Wu, et al.
Published: (2025-08-01)

Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review
by: Aiko Shono, et al.
Published: (2025-12-01)

Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs
by: A. V. Rudakova, et al.
Published: (2019-12-01)

PHARMACOECONOMIC EVALUATION OF ANTI-PNEUMOCOCCAL VACCINATION IN RISK GROUPS FOR THE PREVENTION OF COMMUNITY-ACQUIRED PNEUMONIA AMONG ADULTS IN THE ASTRAKHAN REGION
by: E. A. Orlova, et al.
Published: (2021-05-01)

Analysis of the Compliance of the Vaccination Schedule against Pneumococcal Infection in Young Children
by: I. V. Feldblium, et al.
Published: (2018-10-01)

Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines
by: Laurent Coudeville, et al.
Published: (2025-07-01)

Four-Color Pseudovirus-Based Neutralization Assay: A Rapid Method for Evaluating Neutralizing Antibodies Against Quadrivalent Hand, Foot, and Mouth Disease Vaccine
by: Fan Gao, et al.
Published: (2025-03-01)

Vaccination against Pneumococcal Infections of High-Risk People: Pharmacoeconomic Aspects
by: A. V. Rudakova, et al.
Published: (2020-01-01)